NCCN Guidelines Insights: Prostate Cancer, Version 1.2021: Featured updates to the nccn guidelines

Edward Schaeffer; Sandy Srinivas; Emmanuel S. Antonarakis; Andrew J. Armstrong; Justin E. Bekelman; Heather Cheng; Anthony Victor D'Amico; Brian J. Davis; Neil Desai; Tanya Dorff; James A. Eastham; Thomas A. Farrington; Xin Gao; Eric Mark Horwitz; Joseph E. Ippolito; Michael R. Kuettel; Joshua M. Lang; Rana McKay; Jesse McKenney; George Netto; David F. Penson; Julio M. Pow-Sang; Robert Reiter; Sylvia Richey; Mack Roach; Stan Rosenfeld; Ahmad Shabsigh; Daniel E. Spratt; Benjamin A. Teply; Jonathan Tward; Dorothy A. Shead; Deborah A. Freedman-Cass

doi:10.6004/jnccn.2021.0008

NCCN Guidelines Insights: Prostate Cancer, Version 1.2021: Featured updates to the nccn guidelines

Edward Schaeffer, Sandy Srinivas, Emmanuel S. Antonarakis, Andrew J. Armstrong, Justin E. Bekelman, Heather Cheng, Anthony Victor D'Amico, Brian J. Davis, Neil Desai, Tanya Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Eric Mark Horwitz, Joseph E. Ippolito, Michael R. Kuettel, Joshua M. Lang, Rana McKay, Jesse McKenney, George NettoDavid F. Penson, Julio M. Pow-Sang, Robert Reiter, Sylvia Richey, Mack Roach, Stan Rosenfeld, Ahmad Shabsigh, Daniel E. Spratt, Benjamin A. Teply, Jonathan Tward, Dorothy A. Shead, Deborah A. Freedman-Cass

Research output: Contribution to journal › Article › peer-review

313 Scopus citations

Abstract

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. This article summarizes the panel's discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.

Original language	English (US)
Pages (from-to)	134-143
Number of pages	10
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	19
Issue number	2
DOIs	https://doi.org/10.6004/jnccn.2021.0008
State	Published - Feb 2 2021
Externally published	Yes

Bibliographical note

Funding Information:
This activity is supported by educational grants from Agios Pharmaceuticals; AstraZeneca; Clovis Oncology, Inc.; Daiichi Sankyo; Eisai; Epizyme Inc.; Novartis; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. This activity is supported by an independent medical education grant from Bristol-Myers Squibb, and Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is supported by an independent medical educational grant from Mylan Inc. This activity is supported by a medical education grant from Karyopharm Therapeutics. This activity is supported by an independent educational grant from AbbVie.

Publisher Copyright:
© 2021 Harborside Press. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.6004/jnccn.2021.0008

Find It

Find It at U of M Libraries

Cite this

Schaeffer, E., Srinivas, S., Antonarakis, E. S., Armstrong, A. J., Bekelman, J. E., Cheng, H., D'Amico, A. V., Davis, B. J., Desai, N., Dorff, T., Eastham, J. A., Farrington, T. A., Gao, X., Horwitz, E. M., Ippolito, J. E., Kuettel, M. R., Lang, J. M., McKay, R., McKenney, J., ... Freedman-Cass, D. A. (2021). NCCN Guidelines Insights: Prostate Cancer, Version 1.2021: Featured updates to the nccn guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 19(2), 134-143. https://doi.org/10.6004/jnccn.2021.0008

Schaeffer, E, Srinivas, S, Antonarakis, ES, Armstrong, AJ, Bekelman, JE, Cheng, H, D'Amico, AV, Davis, BJ, Desai, N, Dorff, T, Eastham, JA, Farrington, TA, Gao, X, Horwitz, EM, Ippolito, JE, Kuettel, MR, Lang, JM, McKay, R, McKenney, J, Netto, G, Penson, DF, Pow-Sang, JM, Reiter, R, Richey, S, Roach, M, Rosenfeld, S, Shabsigh, A, Spratt, DE, Teply, BA, Tward, J, Shead, DA & Freedman-Cass, DA 2021, 'NCCN Guidelines Insights: Prostate Cancer, Version 1.2021: Featured updates to the nccn guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 19, no. 2, pp. 134-143. https://doi.org/10.6004/jnccn.2021.0008

@article{5a4a9d3f082f4419bc57d85369523160,

title = "NCCN Guidelines Insights: Prostate Cancer, Version 1.2021: Featured updates to the nccn guidelines",

abstract = "The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. This article summarizes the panel's discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.",

author = "Edward Schaeffer and Sandy Srinivas and Antonarakis, {Emmanuel S.} and Armstrong, {Andrew J.} and Bekelman, {Justin E.} and Heather Cheng and D'Amico, {Anthony Victor} and Davis, {Brian J.} and Neil Desai and Tanya Dorff and Eastham, {James A.} and Farrington, {Thomas A.} and Xin Gao and Horwitz, {Eric Mark} and Ippolito, {Joseph E.} and Kuettel, {Michael R.} and Lang, {Joshua M.} and Rana McKay and Jesse McKenney and George Netto and Penson, {David F.} and Pow-Sang, {Julio M.} and Robert Reiter and Sylvia Richey and Mack Roach and Stan Rosenfeld and Ahmad Shabsigh and Spratt, {Daniel E.} and Teply, {Benjamin A.} and Jonathan Tward and Shead, {Dorothy A.} and Freedman-Cass, {Deborah A.}",

note = "Funding Information: This activity is supported by educational grants from Agios Pharmaceuticals; AstraZeneca; Clovis Oncology, Inc.; Daiichi Sankyo; Eisai; Epizyme Inc.; Novartis; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. This activity is supported by an independent medical education grant from Bristol-Myers Squibb, and Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is supported by an independent medical educational grant from Mylan Inc. This activity is supported by a medical education grant from Karyopharm Therapeutics. This activity is supported by an independent educational grant from AbbVie. Publisher Copyright: {\textcopyright} 2021 Harborside Press. All rights reserved.",

year = "2021",

month = feb,

day = "2",

doi = "10.6004/jnccn.2021.0008",

language = "English (US)",

volume = "19",

pages = "134--143",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "2",

}

TY - JOUR

T1 - NCCN Guidelines Insights: Prostate Cancer, Version 1.2021

T2 - Featured updates to the nccn guidelines

AU - Schaeffer, Edward

AU - Srinivas, Sandy

AU - Antonarakis, Emmanuel S.

AU - Armstrong, Andrew J.

AU - Bekelman, Justin E.

AU - Cheng, Heather

AU - D'Amico, Anthony Victor

AU - Davis, Brian J.

AU - Desai, Neil

AU - Dorff, Tanya

AU - Eastham, James A.

AU - Farrington, Thomas A.

AU - Gao, Xin

AU - Horwitz, Eric Mark

AU - Ippolito, Joseph E.

AU - Kuettel, Michael R.

AU - Lang, Joshua M.

AU - McKay, Rana

AU - McKenney, Jesse

AU - Netto, George

AU - Penson, David F.

AU - Pow-Sang, Julio M.

AU - Reiter, Robert

AU - Richey, Sylvia

AU - Roach, Mack

AU - Rosenfeld, Stan

AU - Shabsigh, Ahmad

AU - Spratt, Daniel E.

AU - Teply, Benjamin A.

AU - Tward, Jonathan

AU - Shead, Dorothy A.

AU - Freedman-Cass, Deborah A.

N1 - Funding Information: This activity is supported by educational grants from Agios Pharmaceuticals; AstraZeneca; Clovis Oncology, Inc.; Daiichi Sankyo; Eisai; Epizyme Inc.; Novartis; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. This activity is supported by an independent medical education grant from Bristol-Myers Squibb, and Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is supported by an independent medical educational grant from Mylan Inc. This activity is supported by a medical education grant from Karyopharm Therapeutics. This activity is supported by an independent educational grant from AbbVie. Publisher Copyright: © 2021 Harborside Press. All rights reserved.

PY - 2021/2/2

Y1 - 2021/2/2

N2 - The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. This article summarizes the panel's discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.

AB - The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. This article summarizes the panel's discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=85100984030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85100984030&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2021.0008

DO - 10.6004/jnccn.2021.0008

M3 - Article

C2 - 33545689

AN - SCOPUS:85100984030

SN - 1540-1405

VL - 19

SP - 134

EP - 143

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 2

ER -

NCCN Guidelines Insights: Prostate Cancer, Version 1.2021: Featured updates to the nccn guidelines

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this